HC Wainwright & Co. Upgrades Sutro Biopharma (STRO)

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks STRO HC Wainwright & Co.

Upgrades Sutro Biopharma (STRO) March 24, 2026 — 08:04 pm EDT Written by George Maybach for Fintel-> Fintel reports that on March 24, 2026, HC Wainwright & Co. upgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Neutral to Buy.

Analyst Price Forecast Suggests 55.41% Upside As of February 25, 2026, the average one-year price target for Sutro Biopharma is $33.15/share. The forecasts range from a low of $8.08 to a high of $105.00. The average price target represents an increase of 55.41% from its latest reported closing price of $21.33 / share. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Sutro Biopharma is 172MM, an increase of 68.00%. The projected annual non-GAAP EPS is -2.37. What is the Fund Sentiment? There are 59 funds or institutions reporting positions in Sutro Biopharma. This is an decrease of 100 owner(s) or 62.89% in the last quarter. Average portfolio weight of all funds dedicated to STRO is 0.08%, an increase of 148.02%. Total shares owned by institutions decreased in the last three months by 90.47% to 5,309K shares. The put/call ratio of STRO is 11.78, indicating a bearish outlook. What are Other Shareholders Doing?

Affinity Asset Advisors holds 748K shares representing 4.57% ownership of the company.

Kynam Capital Management holds 480K shares representing 2.93% ownership of the company. In its prior filing, the firm reported owning 5,088K shares , representing a decrease of 960.93%. The firm increased its portfolio allocation in STRO by 7.75% over the last quarter. Millennium Management holds 418K shares representing 2.55% ownership of the company. In its prior filing, the firm reported owning 4,524K shares , representing a decrease of 981.87%. The firm increased its portfolio allocation in STRO by 21.34% over the last quarter.

Acadian Asset Management holds 338K shares representing 2.06% ownership of the company.

Velan Capital Investment Management holds 312K shares representing 1.90% ownership of the company. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.Click to Learn MoreThis story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags Stocks Fintel Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford. Check out our Unique Analysis of Insider Sentiment for Sutro Biopharma, Inc.-> Find out what the Options Markets think of Sutro Biopharma, Inc.-> See our take on Sutro Biopharma, Inc. Upcoming Earnings-> More articles by this source-> Stocks mentioned STRO More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.